Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging anti-inflammatory agents for allergic rhinitis.

Giorgio Ciprandi1, Giovanni Passalacqua

  • 1Dipartimento Patologie Testa-Collo, Azienda Ospedaliera Universitaria San Martino, Allergologia-U.O. ORL, Largo R. Benzi 10, 16132 Genoa, Italy. gio.cip@libero.it

Expert Opinion on Emerging Drugs
|November 3, 2005
PubMed
Summary

Allergic rhinitis (AR) management is evolving beyond symptom relief. New strategies aim to modify the underlying T helper 2 (TH2)-biased immune response, improving treatments like allergen immunotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Visual Analog Scale for Asthma and Rhinitis Symptoms: Different Approaches of Measurement.

Pediatric pulmonology·2025
Same author

A multidisciplinary Delphi consensus on budesonide aqueous nasal spray in managing upper respiratory diseases.

Multidisciplinary respiratory medicine·2025
Same author

An intranasal multicomponent medical device (Saflovir®) may represent a valuable option in managing upper airways diseases.

Minerva pediatrics·2025
Same author

Ketoprofen and its lysine salt in managing children with fever: evidence emerging from comparative trials.

Panminerva medica·2025
Same author

Survey on the attitude of Italian pediatricians concerning the use of the topical nasal therapy.

Minerva pediatrics·2025
Same author

Relationship between recurrent respiratory infections and allergy: a <i>vexata quaestio</i>.

The Journal of asthma : official journal of the Association for the Care of Asthma·2025

Area of Science:

  • Immunology
  • Allergology
  • Pharmacology

Background:

  • Allergic rhinitis (AR) affects 10-15% of the population, driven by IgE and a complex inflammatory network.
  • The allergic inflammation is fundamentally a T helper 2 (TH2)-biased immune response.
  • Current treatments like drugs offer symptom control but don't alter the immune basis, while immunotherapy has room for improvement.

Purpose of the Study:

  • To explore novel therapeutic strategies for allergic rhinitis.
  • To investigate methods for modifying the TH2-biased immune response in AR.
  • To enhance the efficacy and mechanisms of allergen immunotherapy.

Main Methods:

  • Review of current therapeutic strategies for AR, including pharmacological agents and immunotherapy.
  • Analysis of emerging approaches targeting specific signaling pathways in allergic inflammation.

Related Experiment Videos

  • Exploration of advancements in allergen immunotherapy for modifying immune responses.

    • Main Results:

    • Current drugs provide symptomatic relief but do not address the underlying immune dysregulation in AR.
    • Allergen immunotherapy has the potential to modify the allergic immune response.
    • New drug development and pathway-blocking strategies are under investigation for AR management.

    Conclusions:

    • Optimizing AR management requires addressing the TH2-biased immune response.
    • Improving allergen immunotherapy's characteristics and action modes is a key goal.
    • Future AR therapies focus on modifying the immune background rather than just symptom control.